Filtered By:
Nutrition: Sodium
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 254 results found since Jan 2013.
Clinical characteristics of pediatric narcolepsy learned from screening and enrollment for a phase 3 study of sodium oxybate in children and adolescents
Introduction: Data on pediatric patients with narcolepsy are limited. Therefore, examination of screening samples from pediatric studies provides a meaningful source of additional information. A post hoc analysis of the screening sample from a phase 3, multicenter study of sodium oxybate (SXB) in children and adolescents with pediatric narcolepsy was performed to identify the clinical characteristics of patients referred to the study.
Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: M. Strunc, R. Bogan, Y.G. Wang, R. Parvataneni, M. D'Achille, J. Profant, J. Black, R. Rosenberg Tags: Narcolepsy Source Type: research
Treatment with sodium oxybate decreases body mass index in narcolepsy type 1
Introduction: Individuals with narcolepsy type 1 often gain body weight after disease onset, frequently leading to obesity. Previous work suggested this weight gain may be counteracted by treatment with sodium oxybate (SXB). This has not yet been confirmed, and long-term follow-up data are not available. We assessed body mass index (BMI) change after initiating treatment with SXB and compared this with BMI change after initiating treatment with modafinil in narcolepsy type 1.
Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: M. Schinkelshoek, I. Smolders, C. Donjacour, W. van der Meijden, E. van Zwet, R. Fronczek, G.J. Lammers Tags: Narcolepsy Source Type: research
A double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of sodium oxybate in pediatric subjects with narcolepsy with cataplexy
Introduction: Narcolepsy is a life-long neurological disorder with disease-onset largely occurring during childhood/adolescence. Few treatments have been formally evaluated in pediatric patients. This double-blind placebo-controlled randomized-withdrawal study evaluated the efficacy and safety of sodium oxybate (SXB) in pediatric subjects with narcolepsy with cataplexy.
Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: G. Plazzi, C. Ruoff, M. Lecendreux, Y. Dauvilliers, C. Rosen, J. Black, R. Parvataneni, D. Guinta, Y.G. Wang, E. Mignot Tags: Narcolepsy Source Type: research
Narcolepsy treatments: comparison of pitolisant, modafinil and sodium oxybate via a network meta-analysis
Introduction: Narcolepsy, a chronic disabling disease, is characterized by two main symptoms: the excessive daytime sleepiness (EDS) measured by the Epworth Sleepiness Scale (ESS) and/or the Maintenance Wakefulness Test (MWT) and the cataplexy attacks rate (CAR). We performed a Multiple-Treatment comparison of three main treatments on EDS, CAR and Safety in randomized clinical trials (RCTs) through a Network meta-analysis (NMA).
Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: G. Plazzi, P. Lehert Tags: Narcolepsy Source Type: research
REM sleep-related episodes in children with narcolepsy type 1 after treatment with sodium oxybate
Introduction: Type 1 Narcolepsy (NT1) has been reported to have peculiar clinical features in children. Recently, the occurrence of a severe and peculiar motor disorder during REM sleep in pediatric NT1 has been pointed out (Antelmi et al, 2017). Sodium Oxybate (SO) is used as an off-label treatment in children with NT1, being effective at controlling excessive sleepiness, cataplexy, and disturbed night sleep. Here, we aimed to analyze the effect of this treatment on motor events occurring during nighttime.
Source: Sleep Medicine - December 1, 2017 Category: Sleep Medicine Authors: E. Antelmi, F. Benedetti, F. Pizza, M. Filardi, S. Vandi, R. Liguori, R. Ferri, G. Plazzi Tags: Narcolepsy Source Type: research
What to Eat (and Drink) When You Have the Flu
This article originally appeared on Health.com
Source: TIME: Health - February 6, 2018 Category: Consumer Health News Authors: Amanda MacMillan / Health.com Tags: Uncategorized flu healthytime onetime Source Type: news
Pitolisant (Wakix) for Narcolepsy
Date: February 8, 2021
Issue #:
1617Summary:
The FDA has approved pitolisant (Wakix– Harmony), a
histamine-3 (H3)-receptor antagonist/inverse agonist,
for treatment of excessive daytime sleepiness (EDS)
or cataplexy in adults with narcolepsy. It is the first
H3-receptor antagonist/inverse agonist to become
available in the US and the first non-controlled substance
to receive FDA approval for these indications.
Pitolisant has been available in Europe since 2016.
Source: The Medical Letter - January 12, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Adderall Alertec Amphetamine Anafranil armodafinil Clomipramine Effexor fluoxetine Methylphenidate Narcolepsy Nuvigil pitolisant Provigil Prozac Ritalin SNRIs Sodium oxybate solriamfetol SSRIS Sunosi Tricyclic antid Source Type: research
Deep learning helps CT better quantify COVID-19
Conclusions […..............We demonstrate the anti-IAV activity of WEPO [Portulaca] and strongly recommend the use of WEPO, as an herbal regimen, to prevent and treat H1N1 infection at an early stage] Advice to my patients: If you wish you can use portulaca [as mother tincture in wintertime as it grows only as avegetable during the summer months] Take 30-40 drops if you have/ had a flu, on top of everything else you are doing. [children: 1 year 1/4 dose,3 years 1/3 dose.7 years 1/2 dose,13 years 3/4 dose, between these ages interpolate, anyhow Portulaca is not toxic] Don't take in pregnancy without ...
Source: AuntMinnie.com Headlines - April 2, 2020 Category: Radiology Source Type: news
Narcolepsy and Other Central Hypersomnias
This article focuses on the clinical presentation, pathophysiology, diagnosis, differential diagnosis, and management of narcolepsy type 1 and narcolepsy type 2, idiopathic hypersomnia, Kleine-Levin syndrome, and other central disorders of hypersomnolence, as defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3).
Recent Findings: In ICSD-3, the names of some central disorders of hypersomnolence have been changed: narcolepsy with cataplexy and narcolepsy without cataplexy have been renamed narcolepsy type 1 and narcolepsy type 2, respectively. A low level of hypocretin-1/orexin-A in the CSF...
Source: CONTINUUM: Lifelong Learning in Neurology - August 1, 2017 Category: Neurology Tags: Review Articles Source Type: research
An evaluation of sodium oxybate as a treatment option for narcolepsy.
Authors: Abad VC
Abstract
Introduction: Narcolepsy is a lifelong central nervous system (CNS) disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Treatment is symptomatic and challenging. Current therapies with wake promoting agents, stimulants, and antidepressants improve symptoms but residual sleepiness or cataplexy may persist. Drug tolerance may develop. Adverse drug effects limit therapy. In the United States, sodium oxybate has been approved to treat daytime sleepiness and cataplexy in adults with narcolepsy since 2002. ...
Source: Expert Opinion on Pharmacotherapy - May 30, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Evaluating pitolisant as a narcolepsy treatment option.
Authors: de Biase S, Pellitteri G, Gigli GL, Valente M
Abstract
INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based.
AREAS COVERED: The present manuscript is based on an extensive Internet and PubMed search from 1990 to 2020. It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy.
EXPERT OPINION: Cur...
Source: Expert Opinion on Pharmacotherapy - September 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Solriamfetol Titration & amp; AdministRaTion (START) in Patients With Narcolepsy
This study characterized real-world titration strategies for patients with narcolepsy (with or without comorbid OSA) initiating solriamfetol therapy.METHODS: This virtual, descriptive study included a retrospective medical record review and qualitative survey. US-based physicians prescribing solriamfetol for EDS associated with narcolepsy or OSA participated. Data are reported for patients with narcolepsy with or without comorbid OSA (OSA alone reported separately). On the basis of medical record review, titration strategies were classified de novo (EDS medication naive), transition (switched or switching from existing EDS...
Source: Clinical Therapeutics - September 28, 2022 Category: Drugs & Pharmacology Authors: Michael J Thorpy Danielle Hyman Gregory S Parks Abby Chen Catherine Foley Beth Baldys Diane Ito Haramandeep Singh Source Type: research
Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate
Conclusions:The increased BMI of narcolepsy patients is unlikely to be mediated by hypocretin deficiency-mediated alterations in total ghrelin or leptin levels. Thus, the effects of these hormones on hypocretin neurons may be mainly unidirectional. Although sodium oxybate may influence body weight, the underlying mechanism is unlikely to involve changes in total ghrelin or leptin secretion.Citation:Donjacour CEHM; Pardi D; Aziz NA; Frölich M; Roelfsema F; Overeem S; Pijl H; Lammers GJ. Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium o...
Source: Journal of Clinical Sleep Medicine : JCSM - August 15, 2013 Category: Sleep Medicine Source Type: research
